Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2020-08-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
关于与百济神州有限公司就BAT1706（贝伐珠单抗）签署授权、分销、供货协议的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 百奥泰生物制药股份有限公司 regarding the signing of an authorization, distribution, and supply agreement with 百济神州有限公司 for the drug BAT1706 (Bevacizumab). It details the agreement terms, payment structure, risk analysis, and impact on the company's performance. The document is an announcement of a significant capital/financing transaction involving licensing and milestone payments, but it is not a financial report, earnings release, or regulatory filing. The document length is 3648 characters, which is relatively short and focused on the transaction announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-08-24 Chinese
关于召开2020年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2020 third extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes information on shareholder eligibility, proxy voting, and meeting logistics. There is no financial data, earnings, or report content. The document is an announcement of a shareholder meeting, not the meeting materials or results. It fits the category of a Proxy Solicitation & Information Statement (PSI) as it provides information to shareholders to prepare for voting at the meeting.
2020-08-24 Chinese
关于向香港联交所递交境外上市外资股（H股）上市申请并刊发申请资料的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 百奥泰生物制药股份有限公司 regarding the submission of an application to list foreign shares (H shares) on the Hong Kong Stock Exchange. It mentions the submission of application materials, regulatory approvals pending from Chinese and Hong Kong authorities, and provides links to the application documents on the HKEX website. The document is short (1265 characters) and serves to inform investors about the application and related disclosures rather than containing detailed financial data or the actual application documents themselves. It is an announcement about the filing and publication of application materials, not the materials themselves or a financial report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement that does not fit other specific categories like Capital/Financing Update or M&A Activity, and it is not a report publication announcement because it does not state that a report is attached or published by the company itself but rather provides links to external filings.
2020-08-24 Chinese
关于香港联交所披露2020年度半年度部分财务数据的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 百奥泰生物制药股份有限公司 regarding the disclosure of partial financial data for the half-year ended June 30, 2020, related to its application for listing H shares on the Hong Kong Stock Exchange. It contains unaudited individual balance sheet financial data prepared under IFRS as of June 30, 2020. The document is relatively short (1361 characters) and serves to disclose partial financial data to ensure consistency and timeliness of information disclosure ahead of the formal half-year report, which has not yet been published. It is not a full interim or quarterly report, nor a full annual report, but a regulatory announcement of partial financial data related to a capital market transaction (listing application). Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not constitute a full financial report or other specific filing type.
2020-08-24 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司首次公开发行网下配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from China International Capital Corporation Limited regarding the listing and circulation of restricted shares from the initial public offering (IPO) of Bio-Thera Solutions Ltd. It references specific regulatory approvals, share quantities, lock-up periods, and shareholder commitments related to the IPO and subsequent share circulation. The document is not a financial report, earnings release, or management discussion but rather a formal verification and compliance opinion related to share listing and circulation. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance and verification announcement rather than a financial report or capital update.
2020-08-13 Chinese
首次公开发行网下配售限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It includes specific information about the number of shares becoming tradable, the date of circulation, shareholder commitments, and verification by a sponsoring institution. The document references regulatory approvals and compliance with securities laws but does not contain financial statements or performance data. It is not a full financial report, earnings release, or management discussion. Instead, it is an official announcement about the unlocking and listing of restricted shares for trading. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share circulation and compliance, not a report or presentation.
2020-08-13 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.